Exenatide Pretreatment Improved Graft Function in Nonhuman Primate Islet Recipients Compared to Treatment after Transplant Only
Figure 2
Blood glucose levels measured following intravenous glucose administration (IVGTT) with area under the curve measurements for glucose response for animals treated with ATG/CSA/MMF (a) or exenatide after transplant only (b), untreated (c), and pre-treated with exenatide (d). IVGTTs were performed at baseline prior to pancreatectomy, at day 10 posttransplant for untreated and postexenatide groups, and at day 90 posttransplant for ATG/CSA/MMF and exenatide pre-treatment groups.
